We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.

Delisted

SRNE was delisted on the 22nd of February, 2023.

38 hedge funds and large institutions have $91.5M invested in Sorrento Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

144% more capital invested

Capital invested by funds: $37.5M → $91.5M (+$54M)

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

15% more funds holding

Funds holding: 3338 (+5)

Holders
38
Holders Change
+5
Holders Change %
+15.15%
% of All Funds
1.01%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
12
Increased
13
Reduced
10
Closed
6
Calls
Puts
Net Calls
Net Calls Change

SRNE Hedge Fund Activity: Q4 2014 in Review

38 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2014, worth a combined $91.5M — up 144% from $37.5M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new SRNE positions and 6 closed out — a net gain of 6 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $3.8M. The largest seller was JP Morgan Chase, cutting an estimated $2.44M.

  • 38 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2014, up from 33 in Q3 2014.
  • Funds reported $91.5M of Sorrento Therapeutics, Inc. stock for Q4 2014, up 144% quarter-over-quarter.
  • 12 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2014 and 6 closed out, a net change of +6 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q4 2014 was Cormorant Asset Management, an estimated $3.8M added.
  • The largest Sorrento Therapeutics, Inc. seller in Q4 2014 was JP Morgan Chase, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2014.